Top

BMC Endocrine Disorders

Published in:

Open Access 01-12-2017 | Research article

Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial

Authors: Muhammad M. Hammami, Ahmed Yusuf

Published in: BMC Endocrine Disorders | Issue 1/2017

Abstract

Background

Vitamin D (D) supplements are indispensable for its world-wide deficiency. Controversy continues on ergocalciferol (D2) and cholecalciferol (D3) relative potency as well as on dosing-schedule and sex role in raising 25-hydroxy D (25(OH)D) level, the best indicator of D status.

Methods

We randomized 279 adults to daily D2, D3, D2/D3, or placebo; 2-weekly D2 or D3; or 4-weekly D2 or D3 (250,000 IU over/140 days). Randomization sequence, stratified by body-mass-index (BMI) and sex, was concealed from study coordinators and participants who were then blinded to capsules’ content. D2, D3, 25(OH)D2, and 25(OH)D3 Serum levels were determined blindly on days 0,1,2,3,4,7,14, and 2-weekly thereafter by high performance liquid chromatography assay. The results of 269 participants were available for analysis. Primary endpoint was area-under-the-curve (AUC) of 25(OH)D (25(OH)D2 + 25(OH)D3) adjusted for sex, BMI, and baseline 25(OH)D level.

Results

Mean(SD) age was 33.0(8.5) year, 41% were males, and 85% completed follow-up. Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively. AUC from day 0 to 140 (AUC₁₄₀) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001). 25(OH)D2 AUC₁₄₀ was higher in daily than 2-weekly (17%, p = 0.006) and 4-weekly (20%, p = 0.001) D2-treated groups. 25(OH)D3 AUC₁₄₀ was lower in daily than 2-weekly (11%, p = 0.002) and 4-weekly D3-treated groups (10%, p = 0.008). In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58), in one participant with measurable baseline 25(OH)D2 level, D3 caused a similar decrease in 25(OH)D2 level, while in the D2/D3-treated group, 25(OH)D3 level didn’t increase. Incremental AUC from day 0 to 7 (AUC₇) of D3 and 25(OH)D3 in D3-treated groups were 118–243% higher and 31–39% lower, respectively, than incremental AUC₇ of D2 and 25(OH)D2 in D2-treated groups. Incremental AUC₇ of D3 and 25(OH)D3 in D3-treated groups and D2 and 25(OH)D2 in D2-treated groups were higher in females than males (55, 13, 64, and 28%, respectively). Baseline 25(OH)D level predicted response to D2 and D3 (p < 0.001), whereas, BMI was significant predictor only for early response to D2.

Conclusions

Effects of D2 and D3 supplements on 25 (OH)D level may be dosing-schedule and sex-dependent. D2-associated reduction in 25(OH)D3 level may be related to total 25(OH)D level rather than being D2-specific. D2 may be 25-hydroxylated faster than D3.

Trial registration

ClinicalTrial.gov identifier: NCT01170494 (registered July 25, 2010).

Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26–34. doi:10.1210/jc.2008-1454.CrossRefPubMed

Hollis BW, Wagner CL. The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab. 2013;98(12):4619–28. doi:10.1210/jc.2013-2653.CrossRefPubMedPubMedCentral

Romagnoli E, Carnevale V, Biondi P, Minisola S. Vitamin D supplementation: when and how? J Endocrinol Invest. 2014;37:603–7.CrossRefPubMed

Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96(3):E447–52. doi:10.1210/jc.2010-2230.CrossRefPubMed

Melhem SJ, Aiedeh KM, Hadidi KA. Effects of a 10-day course of a high dose calciferol versus a single mega dose of ergocalciferol in correcting vitamin D deficiency. Ann Saudi Med. 2015;35(1):13–8. doi:10.5144/0256-4947.2015.13.PubMed

Drincic A, Fuller E, Heaney RP, Armas LA. 25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. J Clin Endocrinol Metab. 2013;98(12):4845–51. doi:10.1210/jc.2012-4103.CrossRefPubMed

Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387–91.CrossRefPubMed

Nimitphong H, Saetung S, Chanprasertyotin S, Chailurkit LO, Ongphiphadhanakul B. Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2 supplementation. Nutr J. 2013;12:39. doi:10.1186/1475-2891-12-39.CrossRefPubMedPubMedCentral

Gallo S, Phan A, Vanstone CA, Rodd C, Weiler HA. The change in plasma 25-hydroxyvitamin D did not differ between breast-fed infants that received a daily supplement of ergocalciferol or cholecalciferol for 3 months. J Nutr. 2013;143(2):148–53.CrossRefPubMed

10.

Gordon CM, Williams AL, Feldman HA, May J, Sinclair L, Vasquez A, Cox JE. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008;93(7):2716–21. doi:10.1210/jc.2007-2790.CrossRefPubMedPubMedCentral

11.

Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68(4):854–8.PubMed

12.

Didriksen A, Grimnes G, Hutchinson MS, Kjærgaard M, Svartberg J, Joakimsen RM, Jorde R. The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels. Eur J Endocrinol. 2013;169(5):559–67. doi:10.1530/EJE-13-0233.CrossRefPubMed

13.

Mazahery H, von Hurst PR. Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients. 2015;7(7):5111–42. doi:10.3390/nu7075111.CrossRefPubMedPubMedCentral

14.

Waterhouse M, Tran B, Armstrong BK, Baxter C, Ebeling PR, English DR, Gebski V, Hill C, Kimlin MG, Lucas RM, Venn A, Webb PM, Whiteman DC, Neale RE. Environmental, personal, and genetic determinants of response to vitamin D supplementation in older adults. J Clin Endocrinol Metab. 2014;99(7):E1332–40. doi:10.1210/jc.2013-4101.CrossRefPubMed

15.

Shab-Bidar S, Bours S, Geusens PP, Kessels AG, van den Bergh JP. Serum 25(OH)D response to vitamin D3 supplementation: a meta-regression analysis. Nutrition. 2014;30(9):975–85. doi:10.1016/j.nut.2013.12.020.CrossRefPubMed

16.

Mazahery H, Stonehouse W, von Hurst PR. The effect of monthly 50,000 IU or 100,000 IU vitamin D supplements on vitamin D status in premenopausal Middle Eastern women living in Auckland. Eur J Clin Nutr. 2015;69(3):367–72. doi:10.1038/ejcn.2014.264.CrossRefPubMed

17.

McKibben RA, Zhao D, Lutsey PL, Schneider AL, Guallar E, Mosley TH, Michos ED. Factors associated with change in 25-hydroxyvitamin D levels over longitudinal follow-up in the ARIC study. J Clin Endocrinol Metab. 2016;101(1):33–43. doi:10.1210/jc.2015-1711.CrossRefPubMed

18.

Saliba W, Barnett-Griness O, Rennert G. The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation. Osteoporos Int. 2013;24(4):1447–54. doi:10.1007/s00198-012-2129-0.CrossRefPubMed

19.

Tepper S, Shahar DR, Geva D, Ish-Shalom S. Predictors of serum 25(Oh)D increase following bimonthly supplementation with 100,000IU vitamin D in healthy, men aged 25–65 years. J Steroid Biochem Mol Biol. 2014;144(Pt A):163–6. doi:10.1016/j.jsbmb.2013.12.005.CrossRefPubMed

20.

Gallagher JC, Yalamanchili V, Smith LM. The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women. J Steroid Biochem Mol Biol. 2013;136:195–200. doi:10.1016/j.jsbmb.2012.12.003.CrossRefPubMed

21.

Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One. 2014;9(11):e111265. doi:10.1371/journal.pone.0111265.CrossRefPubMedPubMedCentral

22.

Yousefzadeh P, Shapses SA, Wang X. Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. Int J Endocrinol. 2014;2014:981581. doi:10.1155/2014/981581. 6 pages.CrossRefPubMedPubMedCentral

23.

Møller UK, Streym S, Jensen LT, Mosekilde L, Schoenmakers I, Nigdikar S, Rejnmark L. Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study. Nutrients. 2013;5(9):3470–80. doi:10.3390/nu5093470.CrossRefPubMedPubMedCentral

24.

Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hyppönen E, Berry J, Vieth R, Lanham-New S. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95(6):1357–64. doi:10.3945/ajcn.111.031070.CrossRefPubMedPubMedCentral

25.

Mulligan GB, Licata A. Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. J Bone Miner Res. 2010;25(4):928–30. doi:10.1002/jbmr.67.CrossRefPubMed

26.

Whiting SJ, Bonjour J-P, Payen FD, Rousseau B. Moderate amounts of vitamin D3 in supplements are effective in raising serum 25-hydroxyvitamin D from low baseline levels in adults: a systematic review. Nutrients. 2015;7(4):2311–23. doi:10.3390/nu7042311.CrossRefPubMedPubMedCentral

27.

Aterrado S, Ono G, Kanehira-Mar S, Meier J, Swislocki A. Evaluating vitamin D repletion regimens and effects in veteran patients. Ann Pharmacother. 2015;49(9):969–77.CrossRefPubMed

28.

Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006;84(4):694–7.PubMed

29.

Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93(3):677–81.CrossRefPubMed

30.

Clemens TL, Zhou XY, Myles M, Endres D, Lindsay R. Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab. 1986;63:656–60.CrossRefPubMed

31.

Hartwell D, Hassager C, Christiansen C. Effect of vitamin D2 and vitamin D3 on the serum concentrations of 1,25(OH)2D2 in normal subjects. Acta Endocrinol (Copenh). 1987;115:378–84.

32.

Chel V, Wijnhoven HA, Smit JH, Ooms M, Lips P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int. 2008;19(5):663–71.CrossRefPubMed

33.

Demetriou ET, Travison TG, Holick MF. Treatment with 50,000 IU vitamin D2 every other week and effect on serum 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and total 25-hydroxyvitamin D in a clinical setting. Endocr Pract. 2012;18(3):399–402. doi:10.4158/EP11268.OR.CrossRefPubMed

34.

Macdonald HM, Wood AD, Tang JCY, Fraser WD. Comparison of vitamin D2 and vitamin D3 supplementation in increasing serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(5):1152–3.CrossRefPubMed

35.

Cashman KD, Kiely M, Seamans KM, Urbain P. Effect of ultraviolet light–exposed mushrooms on vitamin D status: liquid chromatography–tandem mass spectrometry reanalysis of biobanked sera from a randomized controlled trial and a systematic review plus meta-analysis. J Nutr. 2016;146(3):565–75.CrossRefPubMed

36.

Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation. J Clin Endocrinol Metab. 2013;98(3):973–9. doi:10.1210/jc.2012-2114.CrossRefPubMedPubMedCentral

37.

Dickert N, Grady C. What’s the price for a research subject? Approaches to payment for research participation. N Engl J Med. 1999;341(3):198–203.CrossRefPubMed

38.

Alvi SN, Yusuf A, Hammami MM. Simultaneous quantification of vitamin D-2, vitamin D-3, and their 25-hydroxy metabolites in human plasma by high performance liquid chromatography. J Bioequiv Availab. 2012;S14:1–5.CrossRef

39.

Randomization.com. Dallal GE. http://www.randomization.com/. Accessed 1 Feb 2017.

40.

Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204–10.PubMed

41.

Cashman KD, Seamans KM, Lucey AJ, Stöcklin E, Weber P, Kiely M, Hill TR. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr. 2012;95(6):1350–6.CrossRefPubMed

42.

Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D’Erasmo E, Carnevale V, Scillitani A, Minisola S. Short and long term variations in serum calciotropic hormones after single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93:3015–20.CrossRefPubMed

43.

Hymøller L, Jensen SK. Vitamin D2 impairs utilization of vitamin D3 in high-yielding dairy cows in a cross-over supplementation regimen. J Dairy Sci. 2011;94(7):3462–6. doi:10.3168/jds.2010-4111.CrossRefPubMed

44.

Tjellesen L, Hummer L, Christiansen C, Rødbro P. Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner. 1986;1(5):407–13.PubMed

45.

Samuel L, Borrell LN. The effect of body mass index on adequacy of serum 25-hydroxyvitamin D levels in US adults: the National Health and Nutrition Examination Survey 2001 to 2006. Ann Epidemiol. 2014;24(10):781–4.CrossRefPubMed

46.

Lin E, Armstrong-Moore D, Liang Z, Sweeney JF, Torres WE, Ziegler TR, Tangpricha V, Gletsu-Miller N. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity (Silver Spring). 2011;19(3):588–94.CrossRef

47.

Aasheim ET, Björkman S, Søvik TT, Engström M, Hanvold SE, Mala T, Olbers T, Bøhmer T. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009;90(1):15–22. doi:10.3945/ajcn.2009.27583.CrossRefPubMed

48.

Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97(1–2):13–9.CrossRefPubMed

49.

Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6–18.PubMed

50.

Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD. Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int. 2011;80(10):1073–9. doi:10.1038/ki.2011.207.CrossRefPubMed

51.

Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, Mayr M, Tam FW. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 2011;80(8):851–60. doi:10.1038/ki.2011.224.CrossRefPubMed

52.

Michelle P, Kayode JB, Hong F, Laurence SM. Increase in vitamin D improves urine protein/creatinine ratio and complement in systemic lupus erythematosus. Arthritis Rheum. 2011;63 Suppl 10:596 [abstract].

53.

Battista C, Viti R, Minisola S, Chiodini I, Frusciante V, Scillitani A, Carnevale V. Over-supplementation of vitamin D in two patients with primary hyperparathyroidism. Hormones. 2013;12(4):598–601. doi:10.14310/horm.2002.1449.CrossRefPubMed

Title: Differential effects of vitamin D2 and D3 supplements on 25-hydroxyvitamin D level are dose, sex, and time dependent: a randomized controlled trial
Authors: Muhammad M. Hammami
Ahmed Yusuf
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Endocrine Disorders / Issue 1/2017
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-017-0163-9

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

Case report: schwannoma arising from the unilateral adrenal area with bilateral hyperaldosteronism